PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update
- Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 - - Nearing Completion of Enrollment of Expansion Phase of EC1169 Trial in Prostate Cancer Patients - - IND filed for Dual-Targeted DNA Crosslinker EC2629 - - Conference Call Today at 4:30 p.m.
View HTML
Toggle Summary Endocyte Announces Second Quarter 2017 Earnings Conference Call
WEST LAFAYETTE, Ind. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Aug. 8th , at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Announces Clinical Updates for EC1456 and EC1169
- Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients -   - Refocusing Efforts on Chimeric Antigen Receptor T-cell (CAR T-cell) and Dual-Targeted DNA Crosslinker Drug EC2629 Programs - - Restructuring to
View HTML
Toggle Summary Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
WEST LAFAYETTE, Ind. , May 26, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets,
View HTML
Toggle Summary Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update
- Conference Call Today at 8:30 a.m. EDT -
View HTML
Toggle Summary Endocyte Announces First Quarter 2017 Earnings Conference Call
WEST LAFAYETTE, Ind. , May 03, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 10th , at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects Resulting from CAR T-Cell Treatment
- Late-breaking poster demonstrates that Endocyte's bi-specific adaptor molecules can mitigate or eliminate cytokine storms - - Potential to meaningfully improve the safety and tolerability of CAR T-cell therapies - WEST LAFAYETTE, Ind. , April 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc.
View HTML
Toggle Summary Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2017
--Presentations to include late-breaker highlighting Endocyte's next generation CAR T-cell therapeutic platform—
View HTML
Toggle Summary Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update
Conference Call Today at 8:30 a.m. EST
View HTML
Toggle Summary Endocyte and Seattle Children's Research Institute to Collaborate on Endocyte's Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules for CAR T-cell Therapies
Collaboration pairs leading SMDC technology with recognized CAR T-cell research expert Plans to develop next generation CAR T-cell therapeutic platform with potential for improved safety and efficacy in solid tumor indications WEST LAFAYETTE, Ind. , March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc.
View HTML